BIOTREATMENT OF PHARMACEUTICAL WASTEWATERS: AN IDEAL APPLICATION FOR MBRs
In September 1998, the United States Environmental Protection Agency (USEPA) promulgated the final rules regarding wastewater effluent guidelines and standards for the pharmaceutical industry. The membrane biological reactor (MBR) represents an ideal biosystem configuration for treatment of pharmaceutical wastewaters, typically variable in composition and volume, and normally containing a number of slowly biodegradable organic compounds. This paper will discuss full scale application of the MBR technology at two different pharmaceutical plant sites in the United States to meet the pretreatment regulations prior to wastewater discharge to the local publicly owned treatment works (POTW). For each of the case studies presented, the use of an MBR has significantly reduced off-site wastewater disposal costs, and the plants that installed the systems are on track for rapid payback on their capital investment.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
Document Type: Research Article
Publication date: 2003-01-01
More about this publication?
- Proceedings of the Water Environment Federation is an archive of papers published in the proceedings of the annual Water Environment Federation® Technical Exhibition and Conference (WEFTEC® ) and specialty conferences held since the year 2000. These proceedings are not peer reviewed. A subscription to the Proceedings of the Water Environment Federation includes access to most papers presented at the annual WEF Technical Exhibition and Conference (WEFTEC) and other conferences held since 2000. Subscription access begins 12 months after the event and is valid for 12 months from month of purchase. A subscription to the Proceedings of the Water Environment Federation is included in Water Environment Federation (WEF) membership.
WEF Members: Sign in (right panel) with your IngentaConnect user name and password to receive complimentary access. Access begins 12 months after the conference or event
- Subscribe to this Title
- Membership Information
- About WEF Proceedings
- WEFTEC Conference Information
- Learn about the many other WEF member benefits and join today
- Ingenta Connect is not responsible for the content or availability of external websites